A Multicenter, Open-label, Clinical Trial to Assess the Effectiveness and Safety of Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced-intensity Conditioning in Relapsed/refractory Anaplastic Large-cell Lymphoma in Children

Akiko Kada; Reiji Fukano; Tetsuya Mori; Michi Kamei; Fumiko Tanaka; Junichi Ueyama; Masahiro Sekimizu; Tomoo Osumi; Takeshi Mori; Yuhki Koga; Kentaro Ohki; Naoto Fujita; Tetsuo Mitsui; Akiko M. Saito; Hiroya Hashimoto; Ryoji Kobayashi

A Multicenter, Open-label, Clinical Trial to Assess the Effectiveness and Safety of Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced-intensity Conditioning in Relapsed/refractory Anaplastic Large-cell Lymphoma in Children

Akiko Kada
, Reiji Fukano
, Tetsuya Mori
, Michi Kamei
, Fumiko Tanaka
, Junichi Ueyama
, Masahiro Sekimizu
, Tomoo Osumi
, Takeshi Mori
, Yuhki Koga
, Kentaro Ohki
, Naoto Fujita
, Tetsuo Mitsui
, Akiko M. Saito
, Hiroya Hashimoto
, Ryoji Kobayashi

研究成果: ジャーナルへの寄稿 › 学術論文 › 査読

抄録

No standard treatment for relapsed or refractory anaplastic large-cell lymphoma (ALCL) has been established. This study is a multicenter, open-label trial to examine the effectiveness and safety of transplantation with reduced-intensity conditioning (RIC) for patients under 20 years old with relapsed or refractory ALCL. We defined RIC as the administration of fludarabine (30 mg/mx²/day) for five days plus melphalan (70 mg/mx²/day) for two days and total body irradiation at 4 Gy, followed by allogeneic hematopoietic stem cell transplantation.

本文言語	英語
ページ（範囲）	89-94
ページ数	6
ジャーナル	Acta Medica Okayama
巻	74
号	1
出版ステータス	出版済み - 2020
外部発表	はい

All Science Journal Classification (ASJC) codes

生化学、遺伝学、分子生物学一般

他のファイルとリンク

フィンガープリント

「A Multicenter, Open-label, Clinical Trial to Assess the Effectiveness and Safety of Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced-intensity Conditioning in Relapsed/refractory Anaplastic Large-cell Lymphoma in Children」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル

Kada, A., Fukano, R., Mori, T., Kamei, M., Tanaka, F., Ueyama, J., Sekimizu, M., Osumi, T., Mori, T., Koga, Y., Ohki, K., Fujita, N., Mitsui, T., Saito, A. M., Hashimoto, H., & Kobayashi, R. (2020). A Multicenter, Open-label, Clinical Trial to Assess the Effectiveness and Safety of Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced-intensity Conditioning in Relapsed/refractory Anaplastic Large-cell Lymphoma in Children. Acta Medica Okayama, 74(1), 89-94.

@article{a110f0b2047e47a8ab456fbfd768c909,

title = "A Multicenter, Open-label, Clinical Trial to Assess the Effectiveness and Safety of Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced-intensity Conditioning in Relapsed/refractory Anaplastic Large-cell Lymphoma in Children",

abstract = "No standard treatment for relapsed or refractory anaplastic large-cell lymphoma (ALCL) has been established. This study is a multicenter, open-label trial to examine the effectiveness and safety of transplantation with reduced-intensity conditioning (RIC) for patients under 20 years old with relapsed or refractory ALCL. We defined RIC as the administration of fludarabine (30 mg/mx2/day) for five days plus melphalan (70 mg/mx2/day) for two days and total body irradiation at 4 Gy, followed by allogeneic hematopoietic stem cell transplantation.",

author = "Akiko Kada and Reiji Fukano and Tetsuya Mori and Michi Kamei and Fumiko Tanaka and Junichi Ueyama and Masahiro Sekimizu and Tomoo Osumi and Takeshi Mori and Yuhki Koga and Kentaro Ohki and Naoto Fujita and Tetsuo Mitsui and Saito, \{Akiko M.\} and Hiroya Hashimoto and Ryoji Kobayashi",

note = "Publisher Copyright: {\textcopyright} 2020 by Okayama University Medical School.",

year = "2020",

language = "English",

volume = "74",

pages = "89--94",

journal = "Acta Medica Okayama",

issn = "0386-300X",

publisher = "Okayama University",

number = "1",

}

Kada, A, Fukano, R, Mori, T, Kamei, M, Tanaka, F, Ueyama, J, Sekimizu, M, Osumi, T, Mori, T, Koga, Y, Ohki, K, Fujita, N, Mitsui, T, Saito, AM, Hashimoto, H & Kobayashi, R 2020, 'A Multicenter, Open-label, Clinical Trial to Assess the Effectiveness and Safety of Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced-intensity Conditioning in Relapsed/refractory Anaplastic Large-cell Lymphoma in Children', Acta Medica Okayama, vol. 74, no. 1, pp. 89-94.

A Multicenter, Open-label, Clinical Trial to Assess the Effectiveness and Safety of Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced-intensity Conditioning in Relapsed/refractory Anaplastic Large-cell Lymphoma in Children. / Kada, Akiko; Fukano, Reiji; Mori, Tetsuya その他.
In: Acta Medica Okayama, Vol. 74, No. 1, 2020, p. 89-94.

研究成果: ジャーナルへの寄稿 › 学術論文 › 査読

TY - JOUR

T1 - A Multicenter, Open-label, Clinical Trial to Assess the Effectiveness and Safety of Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced-intensity Conditioning in Relapsed/refractory Anaplastic Large-cell Lymphoma in Children

AU - Kada, Akiko

AU - Fukano, Reiji

AU - Mori, Tetsuya

AU - Kamei, Michi

AU - Tanaka, Fumiko

AU - Ueyama, Junichi

AU - Sekimizu, Masahiro

AU - Osumi, Tomoo

AU - Mori, Takeshi

AU - Koga, Yuhki

AU - Ohki, Kentaro

AU - Fujita, Naoto

AU - Mitsui, Tetsuo

AU - Saito, Akiko M.

AU - Hashimoto, Hiroya

AU - Kobayashi, Ryoji

PY - 2020

Y1 - 2020

N2 - No standard treatment for relapsed or refractory anaplastic large-cell lymphoma (ALCL) has been established. This study is a multicenter, open-label trial to examine the effectiveness and safety of transplantation with reduced-intensity conditioning (RIC) for patients under 20 years old with relapsed or refractory ALCL. We defined RIC as the administration of fludarabine (30 mg/mx2/day) for five days plus melphalan (70 mg/mx2/day) for two days and total body irradiation at 4 Gy, followed by allogeneic hematopoietic stem cell transplantation.

AB - No standard treatment for relapsed or refractory anaplastic large-cell lymphoma (ALCL) has been established. This study is a multicenter, open-label trial to examine the effectiveness and safety of transplantation with reduced-intensity conditioning (RIC) for patients under 20 years old with relapsed or refractory ALCL. We defined RIC as the administration of fludarabine (30 mg/mx2/day) for five days plus melphalan (70 mg/mx2/day) for two days and total body irradiation at 4 Gy, followed by allogeneic hematopoietic stem cell transplantation.

UR - https://www.scopus.com/pages/publications/85097004338

UR - https://www.scopus.com/pages/publications/85097004338#tab=citedBy

M3 - Article

C2 - 32099255

AN - SCOPUS:85097004338

SN - 0386-300X

VL - 74

SP - 89

EP - 94

JO - Acta Medica Okayama

JF - Acta Medica Okayama

IS - 1

ER -